# Blood Volume Dysfunction in ME/CFS: Synthesis of Mechanisms

**Last Updated:** 2026-01-27

## Overview

Chronic hypovolemia (reduced blood volume) is a well-established feature of ME/CFS with direct clinical consequences for exercise capacity, orthostatic tolerance, and symptom severity. This synthesis integrates findings across 22+ papers to present a unified mechanistic model.

---

## The Central Paradox: RAAS Suppression Despite Hypovolemia

### Expected Physiology
In healthy individuals, reduced blood volume triggers compensatory activation of:
- **Renin-Angiotensin-Aldosterone System (RAAS)** â†’ sodium/water retention
- **Antidiuretic Hormone (ADH)** â†’ water retention
- **Sympathetic nervous system** â†’ vasoconstriction, cardiac output increase

### Observed Pathology in ME/CFS
**Paradoxical suppression** of volume-regulatory systems:

**Key Evidence:**
- **Miwa 2017**: Aldosterone â†“33% (p=0.004), ADH â†“33% (p=0.02) despite documented hypovolemia
- **Raj 2005**: Blood volume â†“17%, plasma volume â†“21% (p<0.0001), yet aldosterone LOW (p=0.01)
- **Mustafa 2011**: Ang II elevated (compensatory), but ACE2 activity reduced (p=0.038)

**Implication:** The evidence suggests hypovolemia most likely results from **central dysregulation** of volume-regulatory hormones rather than excessive fluid loss, though the precise mechanism of this dysregulation remains unknown.

---

## Mechanism 1: RAAS Dysfunction

### RAAS Components Affected

| Component | Normal Response | ME/CFS/POTS Finding | Evidence |
|-----------|----------------|---------------------|----------|
| Plasma Renin Activity | â†‘ in hypovolemia | Paradoxically normal/low | Raj 2005 (n=33) |
| Aldosterone | â†‘ in hypovolemia | Frankly LOW (â†“30-40%) | Miwa 2017, Raj 2005 |
| Angiotensin II | â†‘ moderately | ELEVATED (â†‘50%) | Mustafa 2011, Stewart 2006 |
| ACE2 Activity | Normal | REDUCED (â†“24%, p=0.038) | Mustafa 2011 |
| ADH/Vasopressin | â†‘ in hypovolemia | LOW (â†“33%, p=0.02) | Miwa 2017 |

### Interpretation
- **Elevated Ang II** suggests a compensatory attempt to maintain blood pressure
- **Reduced aldosterone** despite high Ang II is consistent with an **aldosterone synthesis/secretion defect** (though the specific molecular mechanism remains unidentified)
- **Low ADH** compounds volume deficit through inadequate water retention
- **Reduced ACE2** may prolong Ang II effects, potentially contributing to vasoconstriction and NO dysfunction

### Certainty Assessment
- **High certainty**: RAAS suppression replicated across multiple studies
- **Low certainty**: Mechanism of suppression (central? autoimmune? genetic?)

---

## Mechanism 2: Plasma Volume Deficit

### Quantification of Blood Volume Loss

| Study | Method | Sample | Blood Volume Deficit | Plasma Volume Deficit |
|-------|--------|--------|---------------------|----------------------|
| Raj 2005 | Dual isotope | n=33 POTS | -17% (735 mL, p<0.0001) | -21% (591 mL, p<0.0001) |
| van Campen 2018 | Dual isotope | n=20 ME/CFS | -11 ml/kg below reference | Correlated with OI symptoms |
| Farquhar 2002 | Dual isotope | CFS cohort | Trend toward â†“BV | Correlated with VOâ‚‚max |

### Clinical Correlations
- **Orthostatic intolerance**: Severity correlates with degree of volume deficit (van Campen 2018)
- **Exercise capacity**: Blood volume strongly predicts peak VOâ‚‚ (Farquhar 2002)
- **Cardiac preload**: Reduced filling â†’ reduced stroke volume â†’ reduced cardiac output

### Certainty Assessment
- **High certainty**: Plasma volume deficit is real and clinically significant
- **Medium certainty**: Magnitude varies by subgroup (responders to volume expansion?)

---

## Mechanism 3: Cardiac Dysfunction

### Structural Changes

**Newton 2016** (n=42, cardiac MRI):
- End-diastolic volume: REDUCED (p<0.05)
- End-systolic volume: REDUCED (p<0.05)
- End-diastolic wall mass: REDUCED (p<0.05)
- **Critical finding**: No correlation with disease duration â†’ NOT deconditioning

**Strong correlations** (all p<0.01):
- Total blood volume â†” cardiac EDV (r>0.6)
- Plasma volume â†” cardiac EDV (r>0.6)
- RBC volume â†” cardiac wall mass (r>0.5)

### Natriuretic Peptide Elevation

**Tomas 2017**:
- BNP significantly elevated in CFS (p=0.013)
- High BNP (>400 pg/mL) â†’ LOWER cardiac volumes (p=0.05)
- **Paradox**: BNP usually indicates volume overload, but here associates with reduced volumes

**Interpretation**: BNP elevation may reflect **cardiac wall stress** from chronic underfilling rather than fluid retention, though the paradoxical elevation despite reduced cardiac volumes remains mechanistically unexplained.

### Certainty Assessment
- **High certainty**: Cardiac volume reduction is primary, not secondary to deconditioning
- **Medium certainty**: BNP as biomarker (needs replication)

---

## Mechanism 4: Endothelial Dysfunction

### Vascular Pathology

**Scherbakov 2020** (n=35):
- Peripheral endothelial dysfunction: 51% ME/CFS vs 20% controls (p<0.05)
- Assessed via flow-mediated dilation (FMD)
- Correlated with disease severity and immune symptom severity

**Appel 2024** (comprehensive review):
- Elevated adhesion molecules: ICAM-1, VCAM-1
- Impaired FMD across multiple studies
- Chronic inflammation â†’ vascular pathology

### Consequences
1. **Reduced NO bioavailability** â†’ impaired vasodilation
2. **Capillary dysfunction** â†’ tissue hypoperfusion despite adequate systemic blood pressure
3. **Possible plasma leak** â†’ contributes to plasma volume deficit?
4. **Exercise intolerance** â†’ impaired perfusion during exertion

### Links to RAAS
- **Elevated Ang II** (Mustafa 2011) + endothelial dysfunction â†’ vasoconstriction + reduced NO
- **Ang II-mediated oxidative stress** may worsen endothelial function
- Vicious cycle: hypovolemia â†’ Ang II elevation â†’ endothelial damage â†’ further perfusion deficit

### Certainty Assessment
- **High certainty**: Endothelial dysfunction present in significant subset
- **Medium certainty**: Causal contribution to hypovolemia (vs. consequence)

---

## Mechanism 5: Red Blood Cell Dysfunction

### RBC Deformability

**Saha 2019** (n=20 CFS, n=20 controls):
- RBC deformability significantly REDUCED in CFS
- Measured via microfluidic devices
- **Implication**: Even with normal RBC count, oxygen delivery impaired

### Inflammatory Anemia Pattern

**ÅšwiÄ…tczak 2022**:
- Serum iron: LOW
- Ferritin: ELEVATED (inflammation marker)
- Transferrin saturation: REDUCED
- **Pattern**: Anemia of chronic disease (iron sequestration, not deficiency)

### Cytokine-Mediated Erythropoiesis Suppression

**Morceau 2009**, **McCranor 2014**, **Fraenkel 2017**:
- IL-6 directly impairs erythroid differentiation
- Hepcidin (induced by IL-6) sequesters iron
- TNF-Î±, IFN-Î³ suppress EPO production
- Shortened RBC lifespan in inflammatory states

### Integration with ME/CFS Cytokine Data
- **Hornig 2015**: Elevated IL-6, IL-8, TNF-Î± in ME/CFS (especially early disease)
- **Montoya 2017**: Cytokine levels correlate with severity
- **Link**: Elevated cytokines â†’ suppressed erythropoiesis â†’ functional anemia â†’ reduced oxygen delivery

### Certainty Assessment
- **High certainty**: RBC deformability reduced (replicated)
- **Medium-High certainty**: Cytokine-mediated suppression (mechanism well-established in general, specific application to ME/CFS emerging)

---

## Integrated Causal Model: The Hypovolemia Cascade

```
[TRIGGER: Infection, Stress, Trauma]
           â†“
[Central Dysregulation] â† Unknown mechanism (autoimmune? viral persistence? HPA axis?)
           â†“
    â”Œâ”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”
    â†“             â†“
[RAAS Suppression]  [ADH Suppression]
    â†“             â†“
[Aldosterone â†“33%] [ADH â†“33%]
    â†“             â†“
    â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”˜
           â†“
[Inadequate Naâº/Hâ‚‚O Retention]
           â†“
[PLASMA VOLUME â†“21%] â†â”€â”€â”€â”€â”€â”€â”
           â†“                 â”‚
[Cardiac Preload â†“]         â”‚
           â†“                 â”‚
[Cardiac Output â†“] â”€â”€â†’ [Tissue Hypoperfusion]
           â†“                 â†‘
[Exercise Intolerance]       â”‚
           â†“                 â”‚
[PEM Trigger]                â”‚
           â†“                 â”‚
[Cytokine Elevation] â”€â”€â”€â”€â”€â”€â”€â”€â”¤
           â†“                 â”‚
    â”Œâ”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”         â”‚
    â†“             â†“         â”‚
[Endothelial      [RBC Dysfunction]
 Dysfunction]     (â†“deformability)
    â†“             â†“         â”‚
    â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”˜         â”‚
           â†“                â”‚
[Impaired Oâ‚‚ Delivery] â”€â”€â”€â”€â”€â”˜
           â†“
[Symptom Amplification]
```

---

## Why Simple Volume Expansion Fails

**Clinical Observation**: Saline infusions provide only **temporary benefit** (hours to days).

**Explanation via Integrated Model**:
1. **RAAS/ADH suppression persists** â†’ no sustained volume retention
2. **Endothelial dysfunction** â†’ possible plasma leak from vascular to interstitial space
3. **Cytokine-mediated effects continue** â†’ ongoing RBC dysfunction and anemia
4. **Central dysregulation unaddressed** â†’ underlying cause unchanged

**Implication**: Successful treatment requires **multi-component approach**:
- Hormone replacement (desmopressin, fludrocortisone)
- Endothelial function optimization (? antioxidants, ? PAF antagonists)
- Cytokine modulation (? LDN, ? other immunomodulators)
- Address central dysregulation (mechanism unknown)

---

## Subtype Considerations

### Evidence for Heterogeneity

**Desmopressin response** (Miwa 2017):
- 50% of patients improved with ADH analog
- 50% did not respond
- **Question**: Do responders have primary ADH deficiency? Different mechanism?

**Blood volume variability**:
- Not all ME/CFS patients show same degree of hypovolemia
- van Campen 2018: Deficit correlated with OI, but range wide

**Orthostatic intolerance patterns**:
- POTS (HR â†‘30+ bpm)
- Neurally-mediated hypotension (BP drop)
- Delayed orthostatic hypotension
- Overlap significant but not complete

### Proposed Subtypes

| Subtype | Primary Deficit | Blood Volume | RAAS | Treatment Response |
|---------|----------------|--------------|------|-------------------|
| **ADH-deficient** | Low ADH | Moderate â†“ | Normal-low | Desmopressin responder |
| **RAAS-deficient** | Low aldosterone | Marked â†“â†“ | Very low | Fludrocortisone responder |
| **Endothelial** | Vascular leak | Variable | Compensatory â†‘Ang II | ? PAF antagonists |
| **Cytokine-driven** | Inflammatory anemia | Mild â†“ | Variable | Immunomodulation |

**Certainty**: Low (subtype classification speculative, needs validation studies)

---

## Clinical Implications

### Diagnostics

**Tier 1 - Standard Labs:**
- CBC (rule out true anemia)
- Iron panel + ferritin (distinguish iron deficiency from inflammatory anemia)
- Basic metabolic panel (sodium, potassium)

**Tier 2 - Specialized Testing:**
- Plasma renin activity (PRA)
- Plasma aldosterone concentration (PAC)
- ADH/vasopressin level (if available)
- BNP (cardiac stress marker)

**Tier 3 - Research/Specialized Centers:**
- Dual-isotope blood volume measurement (gold standard)
- Flow-mediated dilation (endothelial function)
- RBC deformability testing (research)
- Cytokine panel (IL-6, IL-8, TNF-Î±)

### Treatment Strategies

**Evidence-Based (Medium-High Certainty):**
1. **Increased sodium/fluid intake**: 10-12g sodium/day, 2-3L fluid
2. **Compression garments**: Lower body compression to reduce venous pooling
3. **Desmopressin (ADH analog)**: 0.1-0.2mg oral, trial in ADH-deficient subset
4. **Fludrocortisone**: 0.05-0.2mg/day, mineralocorticoid supplementation

**Emerging (Low-Medium Certainty):**
5. **PAF antagonists** (rupatadine): May address endothelial dysfunction + mast cell activation
6. **Antioxidants** (Coenzyme Q10, Î±-lipoic acid): Endothelial function support
7. **Immunomodulation** (LDN, others): Address cytokine elevation
8. **Erythropoiesis support** (IV iron, ? EPO in select cases)

**Contraindicated:**
- Diuretics (worsen hypovolemia)
- ACE inhibitors (may further suppress aldosterone)
- Aggressive exercise (worsens PEM, cytokines)

### Monitoring Treatment

**Response indicators:**
- Orthostatic symptom reduction
- Exercise capacity improvement (measured via activity tracking, not aggressive testing)
- Cardiac output increase (if measured)
- BNP reduction (if initially elevated)

**Timeline:**
- Acute volume expansion: Hours (temporary)
- Hormone replacement: 2-4 weeks
- Endothelial/cytokine modulation: 8-12 weeks

---

## Research Gaps & Priorities

### Urgent Questions (High Impact)

1. **What causes RAAS/ADH suppression?**
   - Central (hypothalamic/brainstem) lesion?
   - Autoimmune attack on adrenal/pituitary?
   - Persistent viral effects on hormone regulation?
   - Genetic variants in RAAS/ADH genes?

2. **Can we predict treatment responders?**
   - Baseline ADH/aldosterone levels?
   - Genetic markers?
   - Blood volume severity?

3. **What is the role of capillary permeability?**
   - Does plasma leak from vessels to interstitium?
   - Can this be measured (vascular permeability assays)?
   - Does mast cell degranulation contribute (histamine, PAF)?

### Mechanistic Studies Needed

4. **Longitudinal blood volume tracking**
   - Does it worsen over time? Plateau? Improve in remitters?
   - Relationship to disease phases (acute, chronic, severe)?

5. **PEM-specific measurements**
   - Does blood volume drop acutely during PEM?
   - Do cytokines spike first, then volume drops?
   - Can interventions prevent PEM-associated volume loss?

6. **Endothelial function interventions**
   - Can NO donors help (? nitric oxide precursors)?
   - Do PAF antagonists improve vascular function objectively?
   - Role of exercise (carefully graded, below anaerobic threshold)?

### Subtype Validation Studies

7. **Responder phenotyping**
   - Characteristics of desmopressin responders vs non-responders
   - Fludrocortisone responders (baseline aldosterone levels?)
   - Cluster analysis: Are there distinct blood volume phenotypes?

8. **Genetic studies**
   - RAAS gene variants (ACE, AGT, AGTR1, CYP11B2/aldosterone synthase)
   - ADH system genes (AVP, AVPR1A, AVPR2)
   - Endothelial function genes (NOS3, EDNRA)

---

## Alternative Hypotheses and Competing Mechanisms

While the proposed integrated model (RAAS suppression + natriuretic peptide dysregulation + capillary leak â†’ hypovolemia â†’ symptoms) explains the available evidence, alternative mechanisms warrant consideration:

### Alternative 1: Erythropoietin Suppression as Primary Mechanism

**Hypothesis:** Cytokine-mediated suppression of erythropoietin (EPO) and erythropoiesis causes anemia, which produces fatigue and exercise intolerance independent of blood volume loss.

**Evidence supporting:**
- Cytokines (IL-6, TNF-Î±, IFN-Î³) suppress EPO production and erythroid differentiation (Morceau 2009, McCranor 2014, Fraenkel 2017)
- ME/CFS patients show elevated cytokines (Hornig 2015)
- RBC deformability reduced (Saha 2019), impairing oxygen delivery even with normal RBC count
- Inflammatory anemia pattern observed (ÅšwiÄ…tczak 2022)

**Evidence against:**
- Winkler 2004 found EPO levels within normal range in ME/CFS patients (though "normal" may be inappropriately low given context)
- Blood volume deficits are documented by gold-standard measurement (Raj 2005), not just inferred from symptoms
- Hemoglobin levels typically normal or near-normal in ME/CFS, not frankly anemic

**Verdict:** EPO suppression and RBC dysfunction likely **contribute to** oxygen delivery deficits but do not fully explain documented plasma volume reductions. Both mechanisms may operate in parallel.

### Alternative 2: Mitochondrial Dysfunction as Primary Cause

**Hypothesis:** Primary mitochondrial dysfunction impairs cellular ATP production in multiple tissues (kidney, adrenal, cardiac myocytes), with hypovolemia arising secondarily from metabolic failure of volume-regulatory organs.

**Evidence supporting:**
- Mitochondrial dysfunction documented in ME/CFS (see Ch06)
- Renal tubular cells require high ATP for sodium reabsorption; metabolic failure could cause sodium/water loss
- Adrenal steroid synthesis is ATP-dependent; mitochondrial dysfunction could impair aldosterone production
- Autonomic neurons have high metabolic demands; mitochondrial dysfunction could impair ANS function

**Evidence against:**
- No direct evidence that ME/CFS patients have renal or adrenal mitochondrial dysfunction specifically
- RAAS suppression pattern (low renin, low aldosterone, high Ang II) suggests neuroendocrine dysregulation, not metabolic failure of synthesis machinery
- Desmopressin response (50% improvement, Miwa 2017) suggests hormone deficiency, not end-organ resistance

**Verdict:** Mitochondrial dysfunction may **contribute to** autonomic and endocrine dysfunction but does not explain the specific pattern of RAAS suppression. More likely, both are consequences of a common upstream mechanism.

### Alternative 3: Autoimmune Attack on RAAS Components

**Hypothesis:** Autoantibodies target adrenal cortex, pituitary, or hypothalamic neurons regulating RAAS, directly impairing hormone production.

**Evidence supporting:**
- Autoantibodies documented in ME/CFS subset (GPCR antibodies, see Ch07)
- Autoimmune adrenal insufficiency (Addison's disease) causes similar pattern of low aldosterone
- Could explain subset with severe RAAS suppression

**Evidence against:**
- No published studies measuring anti-adrenal antibodies in ME/CFS
- Primary adrenal insufficiency typically presents with low cortisol AND low aldosterone; ME/CFS cortisol levels are variable
- Autoimmune mechanism would not explain natriuretic peptide dysregulation or endothelial dysfunction unless multiple autoimmune targets

**Verdict:** Autoimmune mechanism is plausible for a subset but remains speculative without direct antibody measurement. This is a testable hypothesis requiring prospective study.

### Alternative 4: Peripheral vs. Central Dysfunction

**Question:** Is the primary defect central (hypothalamus/pituitary/brainstem) or peripheral (adrenal/kidney)?

**Central hypothesis:**
- Hypothalamic or brainstem dysfunction impairs central regulation of RAAS and ADH
- Could be caused by viral infection, inflammation, hypoperfusion, or autoimmunity affecting CNS

**Peripheral hypothesis:**
- Adrenal cortex fails to produce aldosterone despite appropriate stimulation
- Juxtaglomerular cells fail to secrete renin despite appropriate sympathetic stimulation
- End-organ resistance rather than central dysregulation

**Current evidence:**
- Sympathetic catecholamine responses are blunted during stress (Strahler 2013) â†’ suggests **central** component
- Ang II is elevated but aldosterone is low (Mustafa 2011) â†’ suggests **adrenal** hyporesponsiveness
- **Likely answer:** Both central AND peripheral dysfunction coexist

**Verdict:** The pattern suggests multilevel dysregulation. Further research with ACTH stimulation testing and direct hypothalamic imaging is needed.

### Why the Integrated Model is Preferred

The integrated model (immune activation â†’ autonomic dysfunction â†’ RAAS/BNP dysregulation â†’ hypovolemia) is preferred because it:

1. **Explains multiple observations** with a unified framework (RAAS suppression, BNP elevation, endothelial dysfunction)
2. **Accounts for treatment responses** (desmopressin, fludrocortisone provide partial benefit)
3. **Integrates across organ systems** (immune, autonomic, cardiovascular, endocrine)
4. **Explains persistence** via feedback loops that maintain dysfunction

However, the model has **critical gaps** (see below) and cannot exclude alternative mechanisms. Most likely, multiple mechanisms operate in parallel, with variable dominance across patient subgroups.

---

## Integration with Other ME/CFS Mechanisms

### Links to Energy Metabolism (Ch06)
- Reduced blood volume may contribute to reduced oxygen delivery and mitochondrial ATP deficit
- Tissue hypoperfusion could promote anaerobic metabolism and lactate accumulation
- RBC dysfunction may impair Oâ‚‚ release to tissues
- **Note:** Causal direction unclearâ€”does hypovolemia cause metabolic dysfunction, or do both result from a common upstream mechanism?

### Links to Immune Dysfunction (Ch07)
- Cytokine elevation (IL-6, TNF-Î± documented in Ch07) can suppress erythropoiesis via established mechanisms
- Immune activation may lead to endothelial activation and vascular dysfunction
- Autoimmune attack on adrenal/RAAS components is plausible but unproven
- **CRITICAL GAP:** The mechanism by which immune activation leads to autonomic dysfunction (and thus RAAS suppression) is unknown and represents a major research priority

### Links to Neurological Dysfunction (Ch08)
- Cerebral hypoperfusion (documented in ME/CFS, Ch08) correlates with reduced cardiac output
- Central dysregulation of RAAS/ADH (hypothalamic dysfunction?) is proposed but mechanistically unverified
- Autonomic nervous system (ANS) failure to appropriately activate RAAS is documented (Strahler 2013), but the cause of ANS dysfunction remains unclear
- **CRITICAL GAP:** Does ANS dysfunction cause hypovolemia, or does hypovolemia impair ANS regulation? Likely bidirectional, but initiating mechanism unknown

### Links to Endocrine Dysfunction (Ch09)
- HPA axis dysfunction â†’ RAAS dysregulation (shared central control)
- Adrenal insufficiency? (low cortisol + low aldosterone in subset)
- Thyroid dysfunction â†’ cardiac output effects

### Links to PEM (Part 1)
- Exercise â†’ cytokine spike â†’ worsened endothelial function + RBC dysfunction
- Tissue hypoperfusion during exertion â†’ post-exertional symptom amplification
- Volume deficit â†’ exercise intolerance (well-established link)

---

## Certainty Summary by Mechanism

| Mechanism | Certainty Level | Evidence Quality | Replication | Clinical Relevance |
|-----------|----------------|------------------|-------------|-------------------|
| RAAS suppression | **High** | Multiple studies, p<0.01 | Replicated (Raj, Miwa) | Direct treatment target |
| Plasma volume deficit | **High** | Gold-standard measurement | Replicated (multiple) | Explains OI, exercise intolerance |
| Cardiac volume reduction | **High** | Cardiac MRI, not deconditioning | Newton 2016 (robust) | Explains hemodynamic dysfunction |
| Endothelial dysfunction | **High** | FMD, adhesion molecules | Multiple studies | Contributes to perfusion deficit |
| RBC deformability | **Medium-High** | Novel tech, needs replication | Saha 2019 (single study) | Oxygen delivery mechanism |
| Inflammatory anemia | **Medium** | Pattern established, mechanism known | ÅšwiÄ…tczak 2022 + general lit | Links cytokines to Oâ‚‚ deficit |
| Desmopressin efficacy | **Medium** | 50% response, small trial | Miwa 2017 (n=10 treatment) | Needs RCT validation |
| Subtype classification | **Low** | Speculative, needs validation | No formal studies | Research priority |
| Central dysregulation cause | **Low** | Unknown mechanism | N/A | Urgent research gap |

---

## References

See `references.bib` for complete citations. Key papers organized in Literature folder:

- **RAAS/**: Miwa 2017, Raj 2005, Mustafa 2011, Stewart 2006, Farquhar 2002, van Campen 2018
- **natriuretic-peptides/**: Tomas 2017, Newton 2016
- **capillary-permeability/**: Scherbakov 2020, Appel 2024, Wirth 2023
- **erythropoietin/**: Saha 2019, ÅšwiÄ…tczak 2022, Morceau 2009, McCranor 2014, Fraenkel 2017

All papers have individual folders with:
- `abstract.txt`
- `notes.md`
- `key-findings.md`
- `integration-guide.md` (for chapter-integrator agent)
- `README.md`

---

## Document Status

- **BibTeX entries**: âœ… All 22 papers added to references.bib
- **Appendix H**: âœ… Comprehensive section added with integrated mechanisms
- **Literature folders**: ðŸŸ¡ Partial (Miwa 2017 complete, others in progress)
- **Chapter integration**: â³ Pending (use integration-guide.md files with chapter-integrator agent)

**Next Steps:**
1. chapter-integrator: Add citations to Ch06 (energy metabolism), Ch09 (endocrine)
2. Complete remaining paper folders (Raj 2005, Newton 2016, Scherbakov 2020, etc.)
3. Create TikZ diagram of hypovolemia cascade for Ch06
4. Add blood volume measurement to Ch02 (diagnostic workup)

---

**Document compiled by:** literature-manager agent
**Date:** 2026-01-27
**Version:** 1.0
